Archie's Corner

[jcradio]

Xechem Announces Issuance of a New Australian Patent for Second Generation Paclitaxel Analogs

February 27, 2001
NEW BRUNSWICK, N.J., Feb 27, 2001 (BUSINESS WIRE) -- Xechem International, Inc. (OTC BB: ZKEM) today announced that the Commissioner of Patents, Commonwealth of Australia Patent Office, granted a second Australian Patent, Patent No. 724929, on January 25th, 2001 to Xechem for its paclitaxel analogs, preparation and use as antitumor agents.
According to Xechem's President & CEO, Dr. Ramesh Pandey, "We are very pleased to receive the second Australian patent on the paclitaxel analogs (also called second generation paclitaxel). This is another example of Xechem's commitment to protect its intellectual property in its growing portfolio of the innovative paclitaxel analogs. We still have over 30 patents pending in this area, as we proceed further into the year 2001 and beyond, we expect many more U.S. and international patents to be issued."

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV) and antifungal compounds. The Company also screens extracts and pure compounds from China and India for their therapeutic use. (See press release of February 14, 2001)

XetaPharm(TM)(another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnce(R), GinsengOnce(R), GarlicOnce(R), Gugulon(TM), and Co-Enzyme Q-10 and numerous products that are under development. (www.xetapharm.com)

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

For further information, contact the President and Chief Executive Officer, Dr. Ramesh C. Pandey at (732) 247 - 3300.

This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.




CONTACT: Xechem International, New Brunswick
Dr. Ramesh C. Pandey, 732/247-3300

URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.




-0-



KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY
LEGAL/LAW
MEDICAL
PHARMACEUTICAL
PRODUCT